1. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ: Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 10: 1793-1800, 1999

2. Hsu CY, McCulloch CE, Curhan GC: Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 13: 2783-2786, 2002

3. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 162: 1401-1408, 2002

4. Gotloib L, Silverberg D, Fudin R, Shostak A: Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 19: 161-167, 2006

5. Mafra D, Cuppari L, Cozzolino SM: Iron and zinc status of patients with chronic renal failure who are not on dialysis. J Ren Nutr 12: 38-41, 2002

6. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft FC: Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26: 292-299, 1995

7. Post JB, Wilkes BM, Michelis MF: Iron deficiency in patients with chronic kidney disease: Potential role for intravenous iron therapy independent of erythropoietin. Int Urol Nephrol 38: 719-723, 2006

8. Eschbach JW: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35: 134-148, 1989

9. Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM: Serum erythropoietin concentration in chronic renal failure: Relationship to degree of anemia and excretory renal function. Blood 54: 877-884, 1979

10. Besarb A: Resolving the paradigm crisis in intravenous iron and erythropoietin management, Kidney International 69: S13-S18, 2006

11. Sargent John A., Acchiardo Sergio R.: Iron Requirements in Hemodialysis Blood Purification, 22:112–123, Memphis, Tenn., USA, 2004

12. Harnett JD, Kent GM, Foley RN, Parfrey PS: Cardiac function and hematocrit level. Am J Kidney Dis 25: S3-S7, 1995

13. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis, British Medical Journal 300: 573-578, 1990

14. Locatelli F. et al.: Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis, Outcomes and Practice Patterns Study (DOPPS), Nephrol Dial Transplant 19: 121–132, 2004

15. Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH: Effect of anaemia on mortality, cardiovascular hospitalizations and end‐stage renal disease among patients with chronic kidney disease. Nephrology (Carlton) 14(2):240-6., 2009

16. Benoist B et al.: Worldwide prevalence of anaemia 1993–2005. WHO Global Database of Anaemia, S1-40, 2008.

17. Stoltzfus RJ; Dreyfuss ML: Guidelines for the Use of Iron Supplements to Prevent and Treat Iron Deficiency Anemia. Int Nutritional Anemia Consultative Group. ILSI Press, S1-46, 1998

18. Singh AK et al.: Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. N Engl J Med 355(20): S2085-2098, 2006

19. Owen WF et al. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients. Am J Kidney Dis 34(4 Suppl 2): S5-S11, 1999

20. Danielson BG et al.: Iron Therapy with Special Emphasis on Intravenous Administration. Switzerland: Vifor (International) Inc. Publisher 1st Edition,1996.

21. Factor KF.: Anemia management in peritoneal dialysis patients: can an iron supplement maintain a normal transferrin saturation and hemoglobin level? Adv Perit Dial 24: 96-98, 2008

22. Fishbane S, Maesaka JK: Iron management in end-stage renal disease. Am J Kidney Dis 29: 319-333, 1997

23. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ: Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 13: 82-88, 1998

24. Akmal M, Sawelson S, Karubian F, Gadallah M: The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol 42: 198-202, 1994

25. Eschbach, JW, Cook, JD, Scribner, BH, Finch, CA.: Iron balance in hemodialysis patients. Ann Intern Med 87: 710, 1977

26. Rosenblatt SG et al.: Gastrointestinal blood loss in patients with chronic renal failure. Am J Kidney Dis 1(4): 232-236, 1982

27. Ifudu O et al.: Relative contributions of body iron status and uremia severity to anemia in patients with advanced chronic renal failure.
Nephron 77(3): 315-318, 1997

28. Crosby William H.: Food Pica and Iron Deficiency. Arch Intern Med (Volume 127): S960-61, 1971

29. Surico G: Parenteral iron supplementation for the treatment of iron deficiency anemia in children. Ann Hematol: S 154-57, 2002

30. Allen Lindsay H: Anemia and iron deficiency: effects on pregnancy outcome. An J Clin Nutr 71 (suppl): S1280-1284, 2000.

31. Eschbach JW: Iron therapy and the anemia of ESRD: historical perspective. Semin Dial 12: 212-218, 1999

32. Hillman RS: Iron deficiency and other hypoproliferative anemias. In Harrison's Principles of Internal Medicine (Edited by: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL). New York: McGraw-Hill. 638-645, 1998

33. Barth RH.: Iron metabolism in end-stage renal disease. Semin Dial
12: 224-30, 1999

34. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative: clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease, 2006. Am J Kidney Dis 47(suppl 3): S1-S146, 2006

35. Locatelli F et al.: Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 24: 348-354, 2009

36. Berns JS et al.: Clinical applications of iron management in hemodialysis patients. Semin Dial 12: 249-256, 1999
37. Besarab A: Iron and cardiac disease in the end-stage renal disease setting.
Am J Kidney Dis 34(suppl 2): S18-S24, 1999

38. Wish JB: Economic issues and future directions in iron management. Semin Dial 12: 267-270, 1999

39. FDA U.S. Food and Drug Administration. Public Health Advisory: Erythropoiesis-Stimulating Agents (ESAs): Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp). Available at: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm054721.htm. Accessed 23 March 2010.

40. Mittal S et al.: Diagnosis of iron deficiency in end-stage renal disease.
Semin Dial 12: 231-234, 1999

41. Agarwal R et al.: Issues related to iron replacement in chronic kidney disease. Semin Nephrol 22(6): 479-487, 2002

42. Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients: Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Nephron 61: 399-403, 1992

43. Koch KM et al.: The use of epoetin beta in anemic predialysis patients with chronic renal failure. Clin Nephrol 44(3): 201-208, 1995

44. Silverberg DS et al.: Intravenous iron for the treatment of predialysis anemia. Kidney Int Suppl 69: S79-85, 1999

45. Van Wyck DB et al.: Just the FAQs: Frequently asked questions about iron and anemia in patients with chronic kidney disease. Am J Kidney Dis 39(2): 426-432, 2002

46. Vychytil A et al.: Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int Suppl 69: S71-78, 1999

47. Van Wyck DB: Management of early renal anaemia: Diagnostic work up, iron therapy, epoetin therapy. Nephrol Dial Transplant 15 (Suppl 3): 36-39, 2000

48. Hörl WH: Iron therapy for renal anaemia: how much needed, how much harmful? Pedatr Nephrol 22: S 480-489, 2007